We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Two Cancer Drugs from Astellas, BMS Win NICE Recommendations

Two Cancer Drugs from Astellas, BMS Win NICE Recommendations

NICE-logo.gif
July 28, 2014

The British healthcare cost evaluation agency has recommended coverage of Astellas Pharma’s prostate cancer drug Xtandi and Bristol-Myers Squibb’s melanoma treatment Yervoy, noting that the therapies provide sufficient gains in overall survival of patients who were treated for the cancers.

The Institute for National Health and Care Excellence (NICE) in guidance last week said a randomized, placebo-controlled study of patients taking 160 mg of Astellas’ Xtandi (enzalutamide) saw a 4.5 month gain in median overall survival until disease progression, which was a “statistically significant” difference in quality of life.

Xtandi reduces the proliferation of prostate cancer cells, stopping the growth of tumors. It is indicated for patients with metastatic hormone-relapsed prostate cancer who have already been treated with a chemotherapy regimen containing docetaxel.

NICE said that the drug will be covered for end-of-life care for patients who have failed two or more chemotherapy regimens. The agency, however, left open the question of recommending Xtandi following treatment of Johnson and Johnson’s Zytiga (aberaterone acetate). In May, NICE partially reversed a January decision to decline this indication, citing a lack of evidence supporting the pairing.

Xtandi gained FDA approval in 2012. This May, Astellas launched the drug in Japan for patients with castration-resistant prostate cancer.

In separate guidance, NICE said a three-armed trial of patients taking Bristol-Myers Squibb’s Yervoy (ipilimumab), plus an investigational gp100 peptide vaccine, showed 3.5 more months of overall survival when compared with patients given only the vaccine.

The guidance concluded that the drug administered intravenously over a 90-minute period at four body-weight-specific dosages over three weeks works better than other available drugs as a first-line therapy for patients with metastatic or unresectable melanoma. Yervoy met the criteria for being a life-extending, end-of-life treatment and that the trial evidence presented for this was robust, the guidance said.

BMS’s Melanie Brunner said that upon its approval in 2011, Yervoy became the first to significantly extend survival in a Phase III study. The NICE guidance “marks a significant milestone for patients in the UK,” she added. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing